Jump to content
Sign in to follow this  
Catharina de Kat

Meeting of the Global Advisory Committee on Vaccine Safety

Recommended Posts

GACVS held its 36th meeting in Geneva, Switzerland, on 7–8 June 2017. The Committee reviewed updates on the safety profiles of Bacillus Calmette-Guérin (BCG) vaccine and human papilloma virus (HPV) vaccine and pharmacovigilance planning for the pilot implementation programme for the antimalaria vaccine. 

Among other findings, the Committee concluded that 

"Ten years after introduction, global HPV vaccine uptake remains slow, and the countries that are most at risk for cervical cancer are those least likely to have introduced the vaccine. Since licensure of HPV vaccines, GACVS has found no new adverse events of concern based on many very large, high quality studies. The new data presented at this meeting have strengthened this position."

Regarding BCG: 

"The vaccine has been shown to be consistently protective against infant tuberculous meningitis and miliary tuberculosis, and remains an important tool for the prevention of tuberculosis"

See the full GACVS meeting report: http://apps.who.int/iris/bitstream/10665/255870/1/WER9228.pdf

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×